FDG-PET/CT for the evaluation of response to therapy of cutaneous T-cell lymphoma to vorinostat (suberoylanilide hydroxamic acid, SAHA) in a phase II trial
- PMID: 18665425
- DOI: 10.1007/s11307-008-0161-4
FDG-PET/CT for the evaluation of response to therapy of cutaneous T-cell lymphoma to vorinostat (suberoylanilide hydroxamic acid, SAHA) in a phase II trial
Abstract
Introduction: Harnessing the power of molecular imaging in particular positron emission tomography (PET) to assess response to therapy in early clinical trials has the potential to yield crucial data on efficacy and streamline drug development. Vorinostat (also known as SAHA, suberoylanilide hydroxamic acid) is a histone deacetylase (HDAC) inhibitor which alters gene transcription to inhibit proliferation and promote apoptosis.
Methods: In a phase II trial of vorinostat for cutaneous T cell lymphoma (CTCL), 2-deoxy-2-[F-18]fluoro-D-glucose (FDG)-PET/computed tomography (CT) was performed on patients with both cutaneous and nodal disease. FDG-PET/CT fuses the power of metabolic imaging from FDG-PET with the anatomic detail of CT. Scans were conducted on subjects pre-therapy and during therapy.
Results: Changes in the values of FDG uptake and measurements of nodal dimensions and thickness of cutaneous lesions were tabulated. FDG-PET/CT provided an objective measure of the response (or lack thereof) of both cutaneous and nodal disease to therapy with vorinostat. The results of this study are encouraging for the potential utility of FDG-PET/CT in future trials with HDAC inhibitors for other diseases and for CTCL with other therapies.
Conclusion: Further study will be required to determine the prognostic value of the initial PET/CT scan and response on follow-up scans.
Similar articles
-
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).Blood. 2007 Jan 1;109(1):31-9. doi: 10.1182/blood-2006-06-025999. Epub 2006 Sep 7. Blood. 2007. PMID: 16960145 Free PMC article. Clinical Trial.
-
FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma.Mol Imaging Biol. 2008 Mar-Apr;10(2):74-81. doi: 10.1007/s11307-007-0127-y. Epub 2008 Jan 15. Mol Imaging Biol. 2008. PMID: 18196347
-
Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.Haematologica. 2010 Apr;95(4):613-21. doi: 10.3324/haematol.2009.013870. Epub 2010 Feb 4. Haematologica. 2010. PMID: 20133897 Free PMC article.
-
Vorinostat in cutaneous T-cell lymphoma.Drugs Today (Barc). 2007 Sep;43(9):585-99. doi: 10.1358/dot.2007.43.9.1112980. Drugs Today (Barc). 2007. PMID: 17940636 Review.
-
Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma.Am J Health Syst Pharm. 2010 May 15;67(10):793-7. doi: 10.2146/ajhp090247. Am J Health Syst Pharm. 2010. PMID: 20479100 Review.
Cited by
-
Total Skin Electron Beam Therapy with Rotary Dual Technique as Palliative Treatment for Mycosis Fungoides.In Vivo. 2018 May-Jun;32(3):517-522. doi: 10.21873/invivo.11269. In Vivo. 2018. PMID: 29695554 Free PMC article.
-
PET in T-Cell Lymphoma.Curr Hematol Malig Rep. 2011 Dec;6(4):241-4. doi: 10.1007/s11899-011-0098-6. Curr Hematol Malig Rep. 2011. PMID: 21892600
-
Nano-based theranostics for chronic obstructive lung diseases: challenges and therapeutic potential.Expert Opin Drug Deliv. 2011 Sep;8(9):1105-9. doi: 10.1517/17425247.2011.597381. Epub 2011 Jun 28. Expert Opin Drug Deliv. 2011. PMID: 21711085 Free PMC article.
-
Recent advances in histone deacetylase targeted cancer therapy.Surg Today. 2010 Sep;40(9):809-15. doi: 10.1007/s00595-010-4300-6. Epub 2010 Aug 26. Surg Today. 2010. PMID: 20740342 Review.
-
Computer-assisted quantitative evaluation of therapeutic responses for lymphoma using serial PET/CT imaging.Acad Radiol. 2010 Apr;17(4):479-88. doi: 10.1016/j.acra.2009.10.026. Epub 2010 Jan 12. Acad Radiol. 2010. PMID: 20060747 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical